Thalassemia

Thalassemia – High-Yield Study Guide for Medical Students

Definition

Thalassemias are inherited quantitative disorders of hemoglobin synthesis characterized by reduced or absent production of one or more globin chains, leading to microcytic anemia, ineffective erythropoiesis, and variable hemolysis. Beta (β) thalassemia involves decreased β-globin chain production, while alpha (α) thalassemia involves impaired α-globin chain synthesis.

Epidemiology

Thalassemias are among the most common monogenic disorders worldwide, with highest prevalence in regions historically endemic for malaria, including the Mediterranean, Middle East, Indian subcontinent, Southeast Asia, and parts of Africa. Carrier frequencies in high-prevalence areas can reach 5–30%. Global migration has made thalassemia an increasingly important hematologic diagnosis in Europe and North America. Disease severity and distribution are shaped by underlying genetic variants, including both coding and non-coding changes in globin clusters and modifier loci that influence phenotype.

Pathophysiology

The core pathophysiology in thalassemia is an imbalance between α- and β-globin chain production, causing ineffective erythropoiesis, hemolysis, and chronic anemia.

Genetic basis: Thalassemias are caused by pathogenic variants in globin genes or their regulatory regions. In β-thalassemia, mutations in the HBB gene (deletions, nonsense, splicing, promoter variants) result in reduced (β₊) or absent (β₀) β-globin synthesis. In α-thalassemia, most defects are deletions of one or more HBA1/HBA2 genes; non-deletional mutations affecting mRNA or protein stability also occur. Non-coding variants in globin and non-globin loci can modulate disease severity by altering gene expression, fetal hemoglobin levels, or erythropoiesis.

Chain imbalance and ineffective erythropoiesis: In β-thalassemia, excess unpaired α chains precipitate in erythroid precursors, generating oxidative damage, membrane injury, and intramedullary apoptosis. In α-thalassemia, excess β- or γ-chains form soluble tetramers (HbH = β₄, Hb Bart's = γ₄) that have high oxygen affinity and contribute to ineffective oxygen delivery. Chronic marrow expansion results from persistent erythropoietin drive, leading to bone deformities and extramedullary hematopoiesis.

Iron overload: Ineffective erythropoiesis suppresses hepcidin, increasing intestinal iron absorption. Combined with transfusional iron in transfusion-dependent phenotypes, this leads to progressive iron overload affecting liver, heart, and endocrine organs. Cardiac and endocrine complications are major determinants of morbidity and mortality in thalassemia major and related severe phenotypes.

Clinical Presentation

Clinical manifestations depend on the type of thalassemia, number of affected alleles, and presence of genetic modifiers:

• β-thalassemia minor (trait): Usually asymptomatic; mild microcytic anemia discovered incidentally. Normal physical exam, no splenomegaly. Important to distinguish from iron deficiency.
• β-thalassemia intermedia: Presents in childhood or later with moderate anemia, variable transfusion requirement, mild to moderate splenomegaly, and features of extramedullary hematopoiesis (e.g., bone changes, gallstones). Iron overload can occur even without regular transfusions.
• β-thalassemia major (Cooley anemia): Infant becomes symptomatic in the first year of life as HbF declines and HbA fails to be produced. Presents with severe transfusion-dependent anemia, failure to thrive, pallor, irritability, jaundice, hepatosplenomegaly, and recurrent infections. Chronic marrow expansion causes characteristic skeletal changes (frontal bossing, maxillary overgrowth, "chipmunk facies"), cortical thinning, and pathologic fractures.
• α-thalassemia silent carrier: Loss of one α gene; clinically normal with minimal microcytosis.
• α-thalassemia trait (two-gene deletion): Mild microcytic anemia, often asymptomatic, frequently mistaken for iron deficiency.
• Hemoglobin H (HbH) disease (three-gene deletion): Moderate to severe hemolytic anemia, jaundice, splenomegaly, sometimes episodic worsening with oxidative stress or infections. May require intermittent transfusions.
• Hydrops fetalis (Hb Bart's, four-gene deletion): Severe intrauterine anemia, hydrops fetalis, and usually intrauterine or early neonatal death without intrauterine transfusion interventions.

Common chronic complications across severe phenotypes include growth delay, delayed puberty, cholelithiasis, leg ulcers, thromboembolic events (especially in splenectomized patients), cardiac failure or arrhythmias, liver disease, and endocrine deficiencies (diabetes, hypogonadism, hypothyroidism, hypoparathyroidism).

Diagnosis

Diagnosis integrates clinical context, red cell indices, peripheral smear, specialized hemoglobin studies, iron status, and molecular testing.

Initial laboratory features:

• Complete blood count (CBC): Microcytic, hypochromic anemia with low MCV and MCH, often with relatively preserved RBC count compared to degree of anemia. RDW is typically normal or mildly elevated (versus markedly elevated in iron deficiency).
• Peripheral smear: Target cells, basophilic stippling, anisopoikilocytosis; nucleated RBCs and teardrop cells in severe disease and in extramedullary hematopoiesis.
• Iron studies: Usually normal or elevated ferritin and transferrin saturation; these are crucial to distinguish thalassemia from iron deficiency before iron therapy is initiated.

Hemoglobin analysis:

• Hemoglobin electrophoresis or HPLC: In β-thalassemia trait, HbA₂ is characteristically elevated (>3.5%), often with increased HbF. In β-thalassemia major, HbA is markedly decreased or absent, with high HbF and variable HbA₂. In α-thalassemia, Hb electrophoresis may be normal in trait; HbH inclusions can be detected with brilliant cresyl blue stain in HbH disease, and Hb Bart's (γ₄) is seen in newborn screening of more severe α-thalassemia.

Molecular and genomic testing:

• DNA-based assays (gap-PCR, MLPA, sequencing) identify α- or β-globin gene deletions, point mutations, and regulatory variants.
• Advanced genomic approaches and analysis of non-coding variants in globin clusters and modifier loci (e.g., BCL11A, HBS1L-MYB) improve prediction of phenotypic severity and inform personalized management in both thalassemia and sickle cell disease.

Additional evaluation includes assessment for iron overload (serum ferritin, liver iron concentration by MRI, cardiac T2* MRI) and screening for organ complications (echocardiography, endocrine testing, liver function tests).

Management

Management depends on disease severity and patient age and aims to correct anemia, prevent or treat complications, and improve quality and length of life.

General Principles

• Mild forms (trait, silent carrier): No specific therapy; emphasize accurate diagnosis, avoidance of unnecessary iron therapy, and genetic counseling regarding reproductive risk when both partners are carriers.
• Moderate to severe forms (β-thalassemia major/intermedia, HbH disease): Require individualized plans including transfusions, iron chelation, supportive care, and consideration of curative options.

Transfusion Therapy

• Indications: Regular transfusions in β-thalassemia major to maintain pre-transfusion hemoglobin around 9–10 g/dL, suppress ineffective erythropoiesis, and prevent skeletal deformities and growth impairment.
• Regimen: Typically every 3–4 weeks, tailored to symptoms, hemoglobin level, and growth parameters.
• Risks: Iron overload, alloimmunization, transfusion reactions, and transfusion-transmitted infections; meticulous blood bank coordination and monitoring are essential.

Iron Chelation

• Indication: Initiated after ~10–20 transfusions or when serum ferritin persistently exceeds threshold values, or when liver iron concentration by MRI is elevated.
• Agents: Parenteral deferoxamine and oral chelators (e.g., deferasirox, deferiprone) are used individually or in combination to reduce hepatic and cardiac iron. Choice depends on age, comorbidities, organ iron burden, and tolerability.
• Monitoring: Serial ferritin, MRI-based iron quantification, and surveillance for chelator toxicity (renal, hepatic, auditory, ocular, hematologic) are required.

Splenectomy

• Indications: Hypersplenism with increasing transfusion requirement, painful splenomegaly, or cytopenias attributable to splenic sequestration.
• Risks: Postsplenectomy sepsis and increased thromboembolic risk; preoperative vaccination and long-term infection prophylaxis strategies should be integrated into care.

Supportive and Preventive Care

• Folate supplementation in transfusion-dependent and hemolytic forms to support erythropoiesis.
• Regular monitoring and management of endocrine, cardiac, and hepatic complications of iron overload.
• Cholelithiasis evaluation and cholecystectomy when indicated.
• Bone health assessment and treatment of osteopenia/osteoporosis.
• Vaccinations and infection prophylaxis, particularly in splenectomized or functionally asplenic patients.

Curative and Disease-Modifying Therapies

• Allogeneic hematopoietic stem cell transplantation (HSCT): Currently the most established curative option, especially effective when performed early in life before significant iron overload or organ damage. Outcomes depend on donor match, transplant conditioning, and baseline risk factors.
• Gene therapy and gene editing: Emerging approaches aim to correct the underlying β-globin defect or reactivate fetal hemoglobin production via lentiviral gene addition or genome editing of regulatory elements. While many data come from sickle cell disease experience, similar strategies apply to transfusion-dependent β-thalassemia.
• Pharmacologic HbF induction and modulators of erythropoiesis: Ongoing research explores agents that modify globin expression and improve ineffective erythropoiesis, leveraging insights from genomic studies of modifier genes and non-coding variants that influence disease severity.

Key Clinical Pearls

• Always differentiate thalassemia trait from iron deficiency anemia; do not start empiric iron supplementation in microcytic anemia without assessing iron status.
• In β-thalassemia trait, elevated HbA₂ is a key diagnostic clue; a normal or low HbA₂ may be misleading if iron deficiency coexists.
• In α-thalassemia trait, hemoglobin electrophoresis can be normal; diagnosis often requires molecular testing or exclusion of other causes of microcytosis.
• Recognize that non-coding variants in globin clusters and modifier genes can significantly alter thalassemia severity, underscoring the importance of comprehensive genetic evaluation in atypical or discordant phenotypes.
• In transfusion-dependent thalassemia, long-term survival hinges on meticulous iron chelation and proactive screening for cardiac and endocrine complications.
• Genetic counseling is essential for at-risk couples, particularly in high-prevalence populations or when one partner is known to carry thalassemia or another hemoglobinopathy such as sickle cell disease.

Exam Tips for Medical Students

• For microcytic anemia with normal or high iron studies and an increased RBC count, think thalassemia rather than iron deficiency.
• On exams, β-thalassemia major often presents with a child with severe anemia, failure to thrive, frontal bossing, and "crew-cut" skull on radiographs due to marrow expansion.
• α-thalassemia hydrops fetalis is classically associated with Hb Bart's (γ₄) and is usually fatal in utero without specialized interventions.
• Understand the difference between quantitative (thalassemia) and qualitative (structural hemoglobin variants like sickle cell disease) hemoglobin disorders, and recognize that they may coexist or interact.